• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2024, Vol. 41 ›› Issue (3): 243-247.

• 药品评价 • 上一篇    下一篇

甘桔冰梅片治疗急性咽炎的临床综合评价

李博1, 叶祖光2, 喻蓉3, 王嘉玺4*   

  1. 1.首都医科大学附属北京中医医院, 北京 100005; 

    2.中国中医科学院中药研究所, 北京 100007; 

    3.重庆市荣昌区中医院, 重庆402460; 

    4.北京中医药大学东方医院, 北京 100078

  • 收稿日期:2024-04-25 修回日期:2024-06-11 出版日期:2024-06-28 发布日期:2024-06-28

Comprehensive Clinical Evaluation of Ganjie Bingmei Tablet in the Treatment of Acute Pharyngitis

  1. 1. Beijing Hospital of Traditional Chinese Medicine, Beijing 100005, China;
    2. Institute of Chinese Materia Medica,Academy of Chinese Medical Sciences, Beijing 100007, China;
    3. Chongqing Rongchang Hospital of Traditional Chinese Medicine, Chongqing 402460, China;
    4. Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
  • Received:2024-04-25 Revised:2024-06-11 Online:2024-06-28 Published:2024-06-28

摘要: 对甘桔冰梅片治疗急性咽炎进行6+1维度临床综合评价。安全性评价显示甘桔冰梅片临床使用中不良反应少,可以确保用药安全,评为A级;有效性系统评价显示甘桔冰梅片治疗急性咽炎的临床有效率与清咽滴丸比有优势(P<0.000 01),甘桔冰梅片对急性咽炎(风热犯肺证)与甘桔清咽颗粒比较有明显的优效性(P<0.05),评为A级;经济学研究显示与清咽滴丸和甘桔清咽颗粒相比,甘桔冰梅片成本更低,是一个绝对优势方案,评为A级;甘桔冰梅片在临床创新和产业创新方面资料充足,创新性评为B级;甘桔冰梅片满足技术需求,适宜性好,评为A级;处方限制较小,药材资源有可持续性,价格处于基药目录与医保目录中咽喉类中成药的低位水平,可及性好,评为A级;甘桔冰梅片组方出自名方“清音丸”,配伍抓住疾病风热犯肺的病机特点,上市后研究总例数超2000例,中医特色较突出,评为A级。临床价值综合评价认为甘桔冰梅片临床价值证据充分,结果确定。

关键词: font-size:medium, ">甘桔冰梅片;急性咽炎;安全性;有效性;临床综合评价

Abstract: The 6+1 dimension clinical comprehensive evaluation of Ganjie Bingmei tablet in the treatment of acute pharyngitis was carried out. Safety evaluation showed that Ganjie Bingmei tablet had few adverse reactions in clinical use, which could ensure drug safety, and was rated as grade A; Systematic evaluation of effectiveness showed that Ganjie Bingmei tablet had better clinical effectiveness than Qingyan dripping pill in the treatment of acute pharyngitis (P<0.000 01), Ganjie Bingmei tablet had better efficacy than Ganjie Qingyan granule in the treatment of acute pharyngitis (syndrome of wind-heat attacking lung) (P<0.05), and was rated as grade A. Economic research shows that compared with Qingyan dripping pills and Ganjie Qingyan granule, Ganjie Bingmei tablet has lower cost and is an absolute advantage program, rated as grade A; Ganjie Bingmei tablet has sufficient data in clinical innovation and industrial innovation, and its innovation is rated as B grade; The Ganjie Bingmei tablet meets the technical requirements, has good suitability, and is rated as grade A; The prescription restriction is small, the medicinal material resources are sustainable, the price is at the low level of the pharyngeal proprietary Chinese medicine in the basic medicine list and the medical insurance list, and the accessibility is good, and it is rated as grade A; Ganjie Bingmei tablet formula comes from the famous prescription "Qingyin pill", which matches the pathogenesis characteristics of wind-heat attacking lung. The total number of cases studied after listing has more than 2000 cases, and the characteristics of traditional Chinese medicine are prominent, and it is rated as grade A. Comprehensive evaluation of clinical value indicates that the clinical value of Ganjie Bingmei tablet is sufficient, and the result is confirmed.

Key words: Ganjie Bingmei tablet, Acute pharyngitis, Security, Effectiveness, Clinical comprehensive evaluation

中图分类号: